Nicox launches Sjögren’s diagnostic test

Article

Sjö is a proprietary laboratory test developed by Immco Diagnostics Inc. which combines traditional markers with three novel, proprietary biomarkers, allowing earlier detection of the disease.

Sophia Antipolis, France-Nicox S.A.recently launched announces that Sjö, an advanced diagnostic panel for the early detection of Sjögren's Syndrome. Nicox also partnered with the Sjögren's Syndrome Foundation to raise awareness among eye care professionals of the disease. Sjögren's Syndrome is estimated to affect about 4 million people in the U.S., with 3 million undiagnosed.

Sjö is a proprietary laboratory test developed by Immco Diagnostics Inc. which combines traditional markers with three novel, proprietary biomarkers, allowing earlier detection of the disease.

Nicox has partnered with the Sjögren's Syndrome Foundation to raise awareness of the prevalence, seriousness, and significance of Sjögren's Syndrome to eyecare professionals. A targeted media campaign over the next few months will aim to educate about the disease and the role they can play in early detection.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
© 2025 MJH Life Sciences

All rights reserved.